 Garden City, NY, Oct. 13, 2021 GLOBE NEWSWIRE -- ProPhase Labs, Inc. NASDAQ: PRPH, a diversified biotech and genomics company, today announces that it expects its Q3 2021 COVID-19 testing revenues to be lower than its Q2 2021 testing revenues given the overall lower levels of COVID-19 testing during the summer months. However, based on the recent uptick in COVID-19 testing due in part to various government and employer-imposed mandates and the Companys growing customer base for testing services, the Company anticipates Q4 2021 COVID-19 testing revenues to be in-line the record levels achieved in Q1 of this year, despite recently decreasing COVID-19 positivity rates. 